BRUSSELS and PERTH, Australia, May 6, 2026 /PRNewswire/ — Radisson Hotel Group is pleased to announce the signing of Radisson Perth, an upscale hotel set within the landmark Sydney Charles Quarter (SCQ) precinct in West Perth, marking the debut of the Radisson brand in Western Australia. The property is expected to open later this year and will represent a significant milestone in the Group’s continued expansion across Australia.

Developed by APPL Group and operated by Mandala Hotels & Resorts, Radisson Perth will form a key part of SCQ, a major mixed-use development designed as a connected village that brings together residential, commercial, and lifestyle elements in one integrated destination.

The hotel will feature 120 rooms and studios, complemented by a rooftop bar and restaurant, meeting spaces, a swimming pool, and a strong focus on guest engagement through art and curated experiences. Its location in West Perth offers strong connectivity to the CBD, key commercial hubs, and major transport links, supporting balanced corporate and leisure demand throughout the year.

“We’re delighted to bring the Radisson brand to this exciting precinct,” said Danilo Curcuruto, Director of Development, Australasia, Radisson Hotel Group. “Radisson Perth is a strong addition to our growing presence in Australia and reflects our focus on partnering with high-quality developments in key urban locations. We are particularly pleased to mark our entry into Western Australia with such a prominent project, in partnership with APPL Group, whose vision and commitment to delivering a standout precinct have been instrumental in bringing this opportunity to life.”

Commenting on the signing, Michelle Prater, Director, APPL Group, said:
“SCQ has been designed as a modern connected village, and the inclusion of Radisson Perth is a key component in bringing that vision to life. We were seeking a brand that stands apart in the market, with a strong identity and the ability to enhance the overall positioning of the village, and Radisson was a natural fit.”

Located on the western fringe of Perth’s CBD, the hotel benefits from proximity to key office precincts, healthcare, and education institutions, as well as retail and dining hubs. The property is well connected to Perth Airport and major transport infrastructure, supporting accessibility for both domestic and international travelers.

Perth continues to strengthen its position as a key gateway to Western Australia, supported by a diverse economy, strong corporate base, and growing tourism appeal. Ongoing infrastructure investment and urban renewal projects, including developments across West Perth and the CBD, are expected to drive sustained demand for well-positioned hotel assets.

Gemma McCourt, Chief Operating Officer at Mandala Hotels & Resorts, added:
“Radisson Perth is an important milestone in Mandala’s national growth strategy and a clear example of the contemporary, experience‑led hotels we are committed to operating across Australia. SCQ is reshaping West Perth, and this hotel will play a defining role in creating a connected, design‑forward precinct that appeals to both corporate and leisure travelers. Its location, product mix, and brand alignment create strong fundamentals for long‑term performance. We’re pleased to partner with Radisson Hotel Group and APPL Group to deliver a hotel that elevates the precinct, strengthens the market, and reflects the confidently different approach Mandala is known for.”

Radisson is an upscale brand that combines contemporary design with a focus on functionality, service, and comfort, catering to both business and leisure travelers. With this signing, Radisson Hotel Group continues to build momentum in Australasia, targeting strategic locations and high-quality developments that align with the evolving needs of owners, investors and guests.

ABOUT RADISSON HOTEL GROUP 

Radisson Hotel Group is a rapidly expanding international hotel group, operating in EMEA and APAC with more than 1,600 hotels in operation and under development in +100 countries. The Group’s overarching brand promise is Every Moment Matters with a signature Yes I Can! service ethos. 

The Radisson brand portfolio includes Radisson Collection, art’otel, Radisson Blu, Radisson, Radisson RED, Radisson Individuals, Park Plaza, Park Inn by Radisson, Country Inn & Suites by Radisson, and Prize by Radisson — brought together under one commercial umbrella brand, Radisson Hotels.  

Radisson Rewards is Radisson Hotel Group’s loyalty program, which delivers an elevated experience that makes Every Moment Matter, counting more than 27 million members. As the most streamlined program in the sector, members enjoy exceptional advantages and can access their benefits from day one across a wide range of hotels in Europe, Middle East, Africa, and Asia Pacific.  

Radisson Meetings provides tailored solutions for any event or meeting, including hybrid solutions, placing guests and their needs at the heart of its offer. Radisson Meetings is built around three strong service commitments: Personal, Professional, and Memorable, while delivering on the brilliant basics and being uniquely Carbon Compensated.  

At Radisson Hotel Group, we care for people, communities, and planet and aim to be Net Zero by 2050 based on the approved Science Based Targets. With unique solutions such as carbon-compensated Radisson Meetings, we make sustainable hotel stays easy. To facilitate sustainable travel choices, all our hotels are becoming verified on Hotel Sustainability Basics. 

The health and safety of guests and team members remain a top priority for Radisson Hotel Group. All properties across the Group’s portfolio are subject to health and safety requirements, ensuring we always care for our guests and team members. 

For more information, visit our corporate website. Or connect with Radisson Hotels on:  

LinkedIn | TikTok | Instagram | Facebook | YouTube | WhatsApp | X 

Source

• Marks five consecutive years of inclusion, reflecting continued progress in ESG management and execution
• Recognition highlights proactive alignment with evolving expectations from global stakeholders

INCHEON, South Korea, May 5, 2026 /PRNewswire/ — Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announced that it has been included in the Dow Jones Best-in-Class World Index (formerly the Dow Jones Sustainability Index) for the fifth consecutive year, reaffirming the company’s continued commitment to sustainable growth and responsible business practices.

The annual index review is based on S&P Global Corporate Sustainability Assessment (CSA), a globally recognized benchmark that evaluates over 2,500 companies across a broad range of environmental, social, and governance (ESG) criteria, including risk management and operational performance. Companies ranked within the top tier of their respective industries are selected for index inclusion.

Samsung Biologics was recognized for its dedication to improving its overall performance through enhanced sustainability data disclosures and the continued advancement of ESG management practices. The company delivered strong results across key areas, including supply chain management, environmental stewardship, and workplace health and safety. These outcomes demonstrate the company’s ability to embed ESG considerations across its operations and business practices.

“This recognition acknowledges our steady progress in strengthening the sustainability management framework across all areas of the business,” said John Rim, President and CEO of Samsung Biologics, who also serves as a champion of the Sustainable Markets Initiative (SMI) Supply Chains Working Group. “We remain committed to responsible growth, transparent operations, and long-term value creation for clients, communities, and stakeholders.”

The continued inclusion also underscores Samsung Biologics’ proactive response to evolving expectations from global investors and stakeholders, while providing objective recognition of the company’s sustainability performance. Samsung Biologics continues to advance its ESG initiatives through disciplined execution, responsible operations, and transparent governance. This year, the company received an EcoVadis Platinum rating and also won a sustainability award at the CDMO Leadership Awards.

About Samsung Biologics

Samsung Biologics (KRX: 207940.KS) is a leading contract development and manufacturing organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing.

With a combined biomanufacturing capacity of 785,000 liters across Bio Campuses I and II in Korea, and 60,000 liters from its manufacturing facility in Rockville, Maryland, U.S., Samsung Biologics holds a total global manufacturing capacity of 845,000 liters. The company has also secured land for Bio Campus III, laying the groundwork for future capacity expansion to support next-generation therapies and emerging modalities.

Samsung Biologics’ global manufacturing and commercial network spans Korea, the U.S., and Japan. Samsung Biologics America supports clients based in the U.S. and Europe, while its Tokyo- and Songdo-based sales offices serve the APAC region.

Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics. By implementing its ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced digitalization, Samsung Biologics ensures plant equivalency and speed for manufacturing continuity.

Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. The company is committed to the on-time, in-full delivery of safe, high-quality biomedicines, as well as to making sustainable business decisions for the betterment of society and global health.

For more information, visit https://samsungbiologics.com/.

Media contacts

Claire Kim, Senior Director cair.kim@samsung.com
Becky Lee, Director brite.lee@samsung.com

Source

GUANGZHOU, China, May 5, 2026 /PRNewswire/ — From surgical robotics to compact massage furniture blending into modern interiors, and eco‑friendly personal‑care products leading a greener shift, a wave of innovation defined by high technology, lightweight design, and sustainability is reshaping the Health & Recreation category at the 139th Canton Fair.

Standing out from the displayed medical equipment, the new orthopedic and endoscopic surgical robots offer greater dexterity and precision, while a mobile capsule endoscopy system enables a painless 20‑minute stomach exam. Its cloud platform supports large‑scale, efficient gastrointestinal screening.

AI is also transforming medical training and diagnostics. Intelligent CPR evaluation systems now automate performance assessment, improving emergency‑response education, while high‑resolution virtual anatomy platforms offer realistic, data‑driven simulation environments. These innovations collectively lower the cost of precision care and expand access to advanced screening tools.

Traditional massage equipment is undergoing a notable shift toward lighter, more aesthetic designs. New “light‑massage” models reduce bulk by nearly a third while integrating entertainment features, wireless charging, and voice interaction. Blow‑molded structures and air‑pressure modules create softer, wave‑like sensations, allowing wellness devices to blend seamlessly into minimalist home spaces.

In maternal care and daily health monitoring, smart wireless thermometers equipped with medical‑grade sensors and cloud‑based apps provide continuous, 24‑hour temperature tracking, addressing the needs of new parents seeking real‑time reassurance.

Eco‑friendly materials and multifunctional design dominate the personal‑care and outdoor‑leisure products. New adhesive‑free cosmetic brush sets use mechanical fastening and biodegradable fibers, reducing environmental impact and storage volume. Natural plant‑fiber bath tools feature modular handles and dual‑mode usability, highlighting sustainable craftsmanship. Electric surf‑assist boards designed for both surface gliding and underwater propulsion, and multi‑sport bags engineered with lightweight waterproof materials and protective hard‑shell structures have also become highlights of the category.

The 139th Canton Fair shows how the boundaries of the Health & Recreation sector are rapidly expanding. Chinese manufacturers are now actively shaping the future of global well‑being.

For pre-registration, please click: https://buyer.cantonfair.org.cn/register/buyer/email?source_type=16

Source

MELBOURNE, Australia and INDIANAPOLIS, Ind., May 5, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the publication of a new independent analysis of Phase 3 ZIRCON trial data in European Urology^[1], demonstrating that TLX250‑Px (Zircaix®^[2], ⁸⁹Zr-girentuximab) PET/CT^[3] imaging may be highly predictive of renal malignancy across all subtypes, not limited to clear cell renal cell carcinoma (ccRCC).

Recognizing that carbonic anhydrase IX (CAIX) expression is also observed in other renal cancer subtypes^[4], this subsequent analysis conducted by international investigators who participated in ZIRCON Phase 3 trial^[5], evaluated centrally reviewed imaging and pathology data to explore whether tracer uptake in renal masses correlated with malignancy beyond ccRCC.

The analysis demonstrated that positive PET findings were highly predictive of malignancy overall, including in non-clear cell renal cell carcinoma (nccRCC), with a reported positive predictive value (PPV) of 98% (95% CI, 96–99), sensitivity of 82% (95% CI, 82–90), and specificity of 87% (95% CI, 81–93). These exploratory scientific findings suggest TLX250-Px has applications beyond the detection of ccRCC in primary renal masses and may have implications to management of nccRCC.

Aboubacar Kaba, MD, urologist at the University of California, Los Angeles and corresponding author, commented: “This analysis shows that when TLX250-Px PET/CT is positive, it is highly predictive of renal malignancy, including beyond ccRCC. Thus, the utility of this test may be important in distinguishing more hypoxic, and therefore, aggressive disease from indolent tumors with clear treatment implications. This may provide an additional tool to aid in risk stratifying or guiding patient and clinician decisions in the treatment of renal masses.”

Dr. David N. Cade, Group Chief Medical Officer at Telix, added: “Publication of these data in European Urology reflects the scientific strength of the ZIRCON trial and the robustness of its central imaging and pathology review. While ZIRCON was designed to address ccRCC, this analysis supports continued evaluation of TLX250-Px PET imaging across a broader spectrum of renal malignancies, with potential application in the management of patients with non-clear cell RCC. Furthermore, essentially all false-positives for ccRCC in the ZIRCON study have now been shown to be other malignant kidney cancer subtypes, reducing the risk of overtreatment and further supporting clinical adoption.”

The full paper is available at: https://www.europeanurology.com/article/S0302-2838(26)02037-3/fulltext.

These findings are based on exploratory analyses and were not the basis of Telix’s Biologics License Application (BLA) submission for TLX250-Px, which focuses exclusively on detection of ccRCC in primary renal masses.

About TLX250-Px

TLX250-Px is a PET imaging candidate under development for the diagnosis and characterization of ccRCC, and included in leading international guidelines for renal imaging^[6]. It works by specifically binding to carbonic anhydrase IX (CAIX), a validated target protein expressed on >95% of ccRCC cells^[7], to produce images with high tumor-to-background ratio and high intra- and inter-reader consistency.

Telix’s pivotal Phase 3 ZIRCON trial evaluating TLX250-Px in 300 patients, of whom 284 were evaluable, met all primary and secondary endpoints, including showing 86% sensitivity and 87% specificity and a 93% positive predictive value (PPV) for ccRCC across three independent radiology readers^[8]. Telix believes this demonstrated the ability of TLX250-Px to reliably detect the clear cell phenotype and provide an accurate, non-invasive method for diagnosing and characterizing ccRCC.

ZIRCON-X, a noninterventional, prospective, post hoc study using imaging data from ZIRCON, found that almost half of all patients (48.6%) would have undergone a change in clinical management if imaged with TLX250-Px, compared with baseline standard-of-care (SOC) imaging, and that more than 20% could potentially have avoided an invasive biopsy^[9].

For more on TLX250-Px and Telix’s theranostic kidney cancer program, click here.

TLX250-Px has not received a marketing authorization in any jurisdiction.

About Telix Pharmaceuticals Limited

Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland) and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

Media Contact

Eliza Schleifstein
917.763.8106 (Mobile)
Eliza@schleifsteinpr.com

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements.  

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification.  To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.

Source

GUANGZHOU, China, May 5, 2026 /PRNewswire/ — On May 2, 2026, during the 139th Canton Fair, Walovi held the Global Partner Conference at its global headquarters on Guangzhou Bio-Island. Over 280 prospective agents, overseas government representatives, industry experts, supply chain partners, and investors gathered to witness Walovi’s latest push in globalization.

Attendees included Zhang Jiong (Vice President of Guangdong Chamber of Import & Export), Cheng Hongjin (Vice President of GPHL), Fang Dafeng (Chairman of Walovi Great Health), and Ye Jizeng (Vice President of Walovi Great Health).The conference targeted partners in 60–80 countries, and Walovi signed distribution agreements with partners from 10 countries across South America, Africa, and Central Asia, expanding its global network into emerging markets.

Cheng Hongjin outlined GPHL’s global strategy as three shifts: from “going out” to “going deep”, from “products” to “system”, and from “trade” to “ecosystem”. He stressed accelerating investment via five prongs, citing the Walovi Global Partner conference as a synergy example.

Fang Dafeng extended an invitation: “We believe that together we can integrate Eastern health wisdom into daily life worldwide, making Walovi a trusted health choice globally.”

Walovi outlined a comprehensive cooperation model featuring regional protection, marketing support, headquarters assistance, and tiered incentives, aiming to add partners in over 60 new countries and regions, especially along the Belt and Road.

The signing ceremony with ten regional distributors from retail, foodservice, and distribution channels marked a strategic extension of Walovi’s global sales network.

According to Frost & Sullivan, Walovi has ranked first globally in natural plant–based beverage sales for five consecutive years. It also leads in global bulk–pack beverage sales, China’s banquet channel, and China’s gift market. Over the past decade, overseas market scale has grown over 6.5 times, with a CAGR exceeding 25%. By deepening localization in markets like Malaysia and Saudi Arabia and launching the WALOVI international can, Walovi has built a global supply chain covering Southeast Asia, the Middle East, and Europe.

Ye Jizeng stated, “Internationalization is not just product export; it means local rooting.” As Walovi aims to become a world–leading natural plant–based beverage company, the conference sent a clear message: riding the global wave of healthy consumption, Walovi is ready to join hands with global partners to create value and win together.

Source

SOFTSWISS, a global technology company providing software for the iGaming industry, celebrates two years of collaboration with Rubens Barrichello, Non-Executive Director in Latin America.

SAO PAULO, May 4, 2026 /PRNewswire/ — Over the past two years of collaboration with Rubens Barrichello, SOFTSWISS has significantly strengthened its presence in Brazil. In Q1 2026, compared to Q1 2025, the B2B tech provider grew total bets by 65% and GGR by 64%.

2 Years of Partnership: SOFTSWISS & Rubens Barrichello

The company has also scaled its local presence from a single representative to a dedicated team focused on business development, account management, and marketing. This expansion improves client service, ensuring timely assistance and project delivery across the region.

As one of Brazil’s most recognised racing figures, Barrichello plays a key role in bridging the company with the local market, supporting educational initiatives and engaging with partners. He has also represented SOFTSWISS at major industry events, including Futurecom 2025 and BiS SiGMA South America 2026.

“I am pleased with our productive partnership. In our third year, our focus is on continuing to build on what we have started. I look forward to helping the team engage partners through racing experiences – it’s a way to share something personal while building real connections,” commented Rubens Barrichello.

Following several rounds of strategic sessions with C-level management, the company has defined key business objectives for 2026. One of the priorities is inspired by Rubens Barrichello’s multidisciplinary experience – delivering solutions faster to accelerate product development and improve productivity across business functions.

Ivan Montik, Founder of SOFTSWISS, commented: “As a lifelong racing fan, I know that in business, just like on the track, milliseconds can define success. Speed and precision matter even more over long distances. This is exactly what Rubens inspires in our daily work. It is this mindset that has helped shape our position in the industry and will continue to drive us forward.”

This focus is already showing results. In just two months, the SOFTSWISS team launched a new B2B product. It enables iGaming operators to offer event-based wagering on real-world events via a fixed-odds model, meeting evolving audience demand while staying within their familiar business domain.

About SOFTSWISS

SOFTSWISS is an international technology company with over 15 years of experience in developing innovative solutions for the iGaming industry. SOFTSWISS provides comprehensive software for managing iGaming projects.

Source